TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04128748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study: NCT04424251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 0.4 μg/kg
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 1 μg/kg
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 0.5μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 1μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage II：HSK21542 0.5μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage II：HSK21542 1μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study: NCT04308590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relacorilant
Description: Relacorilant is supplied as 100 mg capsules for oral dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as 100 mg capsules for oral dosing.
Study: NCT04236804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowly (TMC-CP01)
Description: TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
Study: NCT03268499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol-based transarterial chemoembolization
Description: Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol-based transarterial chemoembolization
Description: Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
Study: NCT01122368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study: NCT04729140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Tablets
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Tablets
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Tablets
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study: NCT01676480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: 12 weeks of endurance training 3 times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: 12 weeks of endurance training 3 times per week
Study: NCT00677027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lentinan
Description: Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT01496573

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01943123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic drink
Description: comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: plain, unsweetend, unflavored pasturised milk
Description: comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
Study: NCT01234402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab DP
Description: 10 mg/kg I.V.~Day 1 of every-21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-18F1
Description: 12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally~Twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally~Twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally~Twice a day for 14 days
Study: NCT02643498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study: NCT02301988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
Study: NCT03859206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: • With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
Study: NCT00883844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue treatment with a peginterferon add-on strategy
Description: peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue treatment
Description: Treatment with one of the approved nucleos(t)ide analogues
Study: NCT02594332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 100 mg SC every 4 weeks for 13 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03866525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection, with or without irinotecan or HX008
Description: OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
Study: NCT02065115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack)
Study: NCT03490279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin CRX
Description: Patients will be asked to take lactoferrin CRX as already mentioned (blindly).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be asked to take placebo as already mentioned (blindly).
Study: NCT04581135

Intervention type: OTHER
Intervention: COVID-19
Description: Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Study: NCT04129502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion
Study: NCT03784365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One dose of Cefo-perazone Sulbactum
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One dose of Cefo-perazone Sulbactum
Description: Antibiotic
Study: NCT02937974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuebijing
Description: Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Study: NCT01669707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar -Continued Pumping into+GP
Description: Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar -injecting into +GP
Description: Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
Study: NCT00990275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethanol
Description: subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
Study: NCT03785288

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR vaginal brachytherapy
Description: HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR vaginal brachytherapy
Description: HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR vaginal brachytherapy
Description: HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR vaginal brachytherapy
Description: HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
Study: NCT04729140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study: NCT03513861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FASTER Assessment tool
Description: The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FASTER Assessment tool
Description: The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
Study: NCT03945253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: Intravenous
Study: NCT02567474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 A model
Description: self management program based on 5A model
Study: NCT03984461

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous cell therapy
Description: Biologic material is harvested from the participant and re-injected into an osteoarthritic joint

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous cell therapy
Description: Biologic material is harvested from the participant and re-injected into an osteoarthritic joint

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous cell therapy
Description: Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
Study: NCT05159739

Intervention type: GENETIC
Intervention: Blood Draw or Saliva/Cheek Cell Sample:
Description: Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
Study: NCT04850365

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteropexy
Description: Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteropexy
Description: Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.
Study: NCT03906474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage controlled human P. falciparum malaria infection
Description: Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage controlled human P. falciparum malaria infection
Description: Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage controlled human P. falciparum malaria infection
Description: Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
Study: NCT02240680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching linagliptin 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: 5 mg once a day
Study: NCT05299710

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
Study: NCT01694875

Intervention type: DEVICE
Intervention: APTIMA HPV Assay
Description: In Vitro Diagnostics Assay
Study: NCT05275270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin gel
Description: The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
Study: NCT02985125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
Study: NCT01891747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 250 mg vitamin C once a day (oral) - Phase I \& Phase II
Study: NCT04676139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 10 mg capsules once daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 12 months
Study: NCT03935477

Intervention type: DEVICE
Intervention: WellBeing catheter
Description: Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension

Intervention type: DEVICE
Intervention: WellBeing catheter
Description: Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
Study: NCT02407574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Pacing Box
Description: Atrial pacing using an external pacing box

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Pacing Box
Description: Atrial pacing using an external pacing box
Study: NCT01888354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel (repository corticotropin injection)
Description: Acthar Gel 80 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel (repository corticotropin injection)
Description: Acthar Gel 80 IU
Study: NCT00554294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: environmental and behavioral change
Description: In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
Study: NCT01581112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial transplant
Description: Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial transplant
Description: Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
Study: NCT00614003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support skills building Intervention
Description: Decision support skills
Study: NCT03907722

Intervention type: OTHER
Intervention: Long pentraxin 3
Description: Primary PCI
Study: NCT02619240

Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: performance of bronchoscopy with BAL
Study: NCT02089386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Study: NCT03777956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo are given as capsules and taken orally twice a day.